Search Result

Results for "

ubiquitination

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) APC (1) Apoptosis (11) AUTACs (1) Autophagy (4) Bcr-Abl (2) Beclin1 (1) CaMK (1) CDK (4) Deubiquitinase (5) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (14) Endogenous Metabolite (2) Ferroportin (1) FKBP (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (2) HSP (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Insulin Receptor (1) Isotope-Labeled Compounds (2) Itk (1) Keap1-Nrf2 (2) Ligands for E3 Ligase (13) Ligands for Target Protein for PROTAC (1) LPL Receptor (2) MDM-2/p53 (2) Mitophagy (1) Molecular Glues (8) Necroptosis (1) NF-κB (2) NO Synthase (1) p62 (4) Phosphatase (1) PROTACs (9) RIP kinase (2) Tau Protein (1) TGF-beta/Smad (1) Topoisomerase (1) YAP (1) β-catenin (1)
By Research Areas:	Cancer (52) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (11)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135199

Ubiquitination-IN-1	E1/E2/E3 Enzyme	Cancer
Ubiquitination-IN-1 (compound 24) is a *ubiquitination* and Cksl-Skp2 protein-protein interaction (IC₅₀=0.17 μM) inhibitor. Ubiquitination-IN-1 increases levels of p27. Ubiquitination-IN-1 has the potential for treatment disease by blocking the degradation of tumor suppressors .

HY-130841

Apcin-A	APC Ligands for Target Protein for PROTAC	Cancer
Apcin-A, an Apcin derivative, is an anaphase-promoting complex (APC) inhibitor. Apcin-A interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V (HY-130257) .

HY-152266

Ubiquitination-IN-2	E1/E2/E3 Enzyme	Cancer
Ubiquitination-IN-2 is a potent E1-E2 protein−protein interactions (PPI) inhibitor. Ubiquitination-IN-2 has a K_d value of 0.72 μM for ubiquitin E1 (Uba1). Ubiquitination-IN-2 inhibits blocks ubiquitin transfer from E1 to E2. Ubiquitination-IN-2 can be used in research of cancer .

HY-150411

Cys-C-cGMP

AUTACs Cancer

Cys-C-cGMP is a autophagy tag for AUTACs. Cys-C-cGMP can increase the K63-linked ubiquitination of mitochondria in HeLa cells .

Cys-C-cGMP	AUTACs	Cancer
Cys-C-cGMP is a autophagy tag for AUTACs. Cys-C-cGMP can increase the K63-linked ubiquitination of mitochondria in HeLa cells .

HY-156959

Ovalicin	Others	Others
Ovalicin is a potent angiogenesis inhibitor. Ovalicin can be used for the preparation of targeting ubiquitination composition libraries which can be used to identify proteins involved in a predetermined function of cells .

HY-W020033

Lanosterol 2 Publications Verification	Endogenous Metabolite	Neurological Disease
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

HY-144971

dCeMM2	Molecular Glues CDK	Cancer
dCeMM2 (Compound 2) is a glue degrader. dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-144976

dCeMM3	Molecular Glues CDK	Cancer
dCeMM3 (Compound 3) is a glue degrader. dCeMM3 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-144977

dCeMM4	Molecular Glues CDK	Cancer
dCeMM4 (Compound 5) is a glue degrader. dCeMM4 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex .

HY-147088

TEAD-IN-2	YAP	Cancer
TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain (TEAD) and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD .

HY-153775

UC-764864	E1/E2/E3 Enzyme	Cancer
UC-764864 is a UBE2N inhibitor. UC-764864 inhibits UBE2N enzymatic activity. UC-764864 has cytotoxic effects and inhibition of UBE2N-dependent signaling in leukemic cells. UC-764864 blocks ubiquitination of innate immune- and inflammatory-related substrates in human AML cell lines .

HY-W181530

NCT02	CDK	Cancer
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .

HY-139662

HB007	E1/E2/E3 Enzyme	Cancer
HB007 is a *small ubiquitin-related modifier 1 (SUMO1)* degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers .

HY-18643

TZ9 2 Publications Verification	E1/E2/E3 Enzyme Apoptosis	Cancer
TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells .

HY-149760

PVD-06	Phosphatase	Cancer
PVD-06 is a selective PTPN2 degrader (PTPN2/PTP1B selectivity index >60-fold) and induces PTPN2 degradation in a ubiquitination- and proteasome-dependent manner. PVD-06 promotes T cell activation and amplifies IFN-γ-mediated cytotoxicity. PVD-06 has anticancer activity .

HY-115461

MID-1	Insulin Receptor	Metabolic Disease
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .

HY-147025

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine 1 Publications Verification	PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia .

HY-18638

TCID 1 Publications Verification 4,5,6,7-Tetrachloroindan-1,3-dione	Deubiquitinase	Neurological Disease
TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective *neuronal ubiquitin* C-terminal hydrolase (UCH-L3) inhibitor with an IC₅₀** of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .

HY-124713

ML372	DNA/RNA Synthesis	Neurological Disease
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .

HY-110261

GS143	IKK E1/E2/E3 Enzyme NF-κB	Inflammation/Immunology
GS143 is a selective IκBα ubiquitination inhibitor with an IC₅₀ of 5.2 μM for SCF ^βTrCP1-mediated IκBα ubiquitylation. GS143 suppresses NF-κB activation and transcription of target genes and does not inhibit proteasome activity. GS143 has anti-asthma effect .

HY-153322

ITK degrader 2

Itk Cancer

ITK degrader 2 (compound 30) is a modulator of targeted ubiquitination and a targeted protein degrading molecule. ITK degrader 2 degrades ITK .

ITK degrader 2	Itk	Cancer
ITK degrader 2 (compound 30) is a modulator of targeted ubiquitination and a targeted protein degrading molecule. ITK degrader 2 degrades ITK .

HY-112438

MF-094 3 Publications Verification	Deubiquitinase	Cancer
MF-094 is a potent and selective USP30 inhibitor with an IC₅₀ of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .

HY-141659

CMPD-39 1 Publications Verification	Deubiquitinase	Cancer
CMPD-39 is a selective USP30 inhibitor with an IC₅₀ of 0.02 μM. CMPD-39 increases protein ubiquitination and accelerates mitophagy .

HY-122550

Artemisitene	Keap1-Nrf2 Topoisomerase Apoptosis	Cancer
Artemisitene, a natural derivative of Artemisinin, is a Nrf2 activator with antioxidant and anticancer activities. Artemisitene activates Nrf2 by decreasing Nrf2 ubiquitination and increasing its stability .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin	Cancer
xStAx-VHLL TFA, a PROTAC, sustains β-catenin degradation and manifested strong inhibition of Wnt signaling. xStAx-VHLL TFA promotes β-catenin ubiquitination .

HY-138641

Bavdegalutamide 2 Publications Verification ARV-110	Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer .

HY-W020033S

Lanosterol-d6	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease
Lanosterol-d₆ is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s

HY-110182

SP-141 1 Publications Verification	MDM-2/p53	Cancer
SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .

HY-15301

CC0651	E1/E2/E3 Enzyme	Cancer
CC0651 is an allosteric inhibitor of the human *Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC₅₀=1.72 μM) inhibits the ubiquitination* of p27 ^Kip1, as confirmed by dose-response analysis.

HY-115715

EN219	E1/E2/E3 Enzyme	Cancer
EN219 is a moderately selective synthetic covalent ligand against an N-terminal cysteine (C8) of RNF114 with an IC₅₀ of 470 nM. EN219 inhibits RNF114-mediated autoubiquitination and p21 ubiquitination .

HY-128807

E3 ligase Ligand 10	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-129653

E3 ligase Ligand 18	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 18 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 18 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128811

E3 ligase Ligand 14	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-43961

E3 ligase Ligand 8 3 Publications Verification	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 8 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 8 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128810

E3 ligase Ligand 13	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 13 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 13 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-128806

E3 ligase Ligand 9	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins .

HY-138669

C004019	PROTACs Tau Protein	Neurological Disease
C004019 is a small-molecule PROTAC. C004019 simultaneously recruites tau and E3-ligase (Vhl) and thus selectively enhances ubiquitination and proteolysis of tau proteins. C004019 can be used for Alzheimer disease (AD) research .

HY-130800

Eragidomide 1 Publications Verification CC-90009	Ligands for E3 Ligase Molecular Glues Apoptosis	Inflammation/Immunology Cancer
Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 ^CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation .

HY-13814

PR-619 10+ Cited Publications	Deubiquitinase Autophagy Apoptosis	Cancer
PR-619 is a broad-range and reversible DUB inhibitor with EC₅₀s of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for USP4, USP8, USP7, USP2, and USP5, respectively. PR-619 induces ER Stress and ER-Stress related apoptosis .

HY-112220

VIT-2763 1 Publications Verification	Ferroportin	Metabolic Disease
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .

HY-N5024

Gambogenic acid 1 Publications Verification	Histone Methyltransferase	Cancer
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer .

HY-130297

PROTAC BCR-ABL1 ligand 1	Bcr-Abl	Cancer
PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1 .

HY-130257

CP5V	PROTACs	Cancer
CP5V is a PROTAC connected by ligands for von Hippel-Lindau and CDK, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation .

HY-133869

cGMP-HTL cGMP-HaloTag-ligand	Autophagy	Cancer
cGMP-HTL contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag). cGMP-HTL increases the K63-linked ubiquitination of mitochondria. AUTAC (autophagy-targeting chimera) is a novel targeted-clearance strategy that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity .

HY-P3709

TRAF6 peptide	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-P3709A

TRAF6 peptide TFA	p62 E1/E2/E3 Enzyme	Neurological Disease
TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .

HY-157416

COP1-ATGL modulator 1	Others	Metabolic Disease
COP1-ATGL modulator 1 (86) is an orally active modulator for COP1-ATGL axis. COP1-ATGL modulator 1 (86) could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range .

HY-125834

GMB-475	PROTACs Bcr-Abl Apoptosis	Cancer
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent agent resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein .

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-100487

TAK-243 25+ Cited Publications MLN7243	E1/E2/E3 Enzyme NF-κB Apoptosis	Cancer
TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC₅₀=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library

286 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 286 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

HY-L137

Molecular Glue Compound Library

35 Compounds compounds

Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention.

Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy.

MCE supplies a unique collection of 35 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

HY-L129

Target Protein Ligand Library

39 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 39 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L128

E3 Ligase Ligand Library

88 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 88 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W020033

Lanosterol 2 Publications Verification	Triterpenes Structural Classification Human Gut Microbiota Metabolites Microorganisms Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .

HY-122550

Artemisitene	Piscidia erythrina L. Terpenoids Sesquiterpenes Source classification Plants Compositae	Keap1-Nrf2 Topoisomerase Apoptosis
Artemisitene, a natural derivative of Artemisinin, is a Nrf2 activator with antioxidant and anticancer activities. Artemisitene activates Nrf2 by decreasing Nrf2 ubiquitination and increasing its stability .

HY-N5024

Gambogenic acid 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Guttiferae Phenols Polyphenols Plants Garcinia hanburyi Hook. f. Disease Research Fields Cancer	Histone Methyltransferase
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer .

Species:	Human (3)
Tag:	His (1) Tag Free (1) GST (1)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P701512

	SMURF2 Protein, Human (His) SMURF2; E3 ubiquitin-protein ligase SMURF2; hSMURF2; HECT-type E3 ubiquitin transferase SMURF2; SMAD ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2	Human	E. coli
	SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human (His) is the recombinant human-derived SMURF2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SMURF2 Protein, Human (His) is 747 a.a., .

HY-P701513

	SMURF2 Protein, Human SMURF2; E3 ubiquitin-protein ligase SMURF2; hSMURF2; HECT-type E3 ubiquitin transferase SMURF2; SMAD ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2	Human	E. coli
	SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human is the recombinant human-derived SMURF2 protein, expressed by E. coli , with tag free. The total length of SMURF2 Protein, Human is 747 a.a., .

HY-P700392

	UBAC1 Protein, Human (GST) UBAC1; UBA domain containing 1; UBADC1, ubiquitin associated domain containing 1; ubiquitin-associated domain-containing protein 1; GBDR1; UBA domain-containing protein 1; E3 ubiquitin-protein ligase subunit KPC2; ubiquitin associated domain containing 1; kip1 ubiquitination-promoting complex protein 2; glialblastoma cell differentiation-related protein 1; putative glialblastoma cell differentiation-related protein; UBADC1; RP11-432J22.3	Human	E. coli
	UBAC1 protein, a non-catalytic component of the KPC complex, aids in polyubiquitination, targeting proteins like CDKN1B and NFKB1. The KPC complex regulates the cell cycle by ubiquitinating and degrading CDKN1B during the G1 phase. Additionally, it influences NF-kappa-B signaling by promoting NFKB1 maturation. Within the KPC complex, UBAC1 acts as an adapter, facilitating the transfer of polyubiquitinated proteins to the proteasome, emphasizing its role in protein ubiquitination processes. UBAC1 Protein, Human (GST) is the recombinant human-derived UBAC1 protein, expressed by E. coli, with N-GST labeled tag. The total length of UBAC1 Protein, Human (GST) is 405 a.a., with molecular weight of 72.3 kDa.

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].